Management of Post‑Inhaler Discontinuation Cough in Children

Immediate Management

Restart the inhaled corticosteroid (ICS) at the same dose that was being used before the abrupt stop, because loss of controller therapy can quickly lead to loss of asthma control and cough. 3
Provide an as‑needed short‑acting beta‑agonist (SABA) for symptom relief while the controller is being re‑started. 1
Use a large‑volume spacer with the metered‑dose inhaler to ensure optimal drug delivery in a 4‑year‑old child. 3

The absence of audible wheeze does not rule out asthma; cough alone can be the sole manifestation of an exacerbation or loss of control, especially in young children. 1
Recurrent cough is a common presentation of childhood asthma and is frequently triggered by viral infections, exercise, or after discontinuation of controller medication. 1
The British Thoracic Society recommends that any child with a known history of wheeze who presents with recurrent cough should be managed according to asthma protocols. 1

Symptom resolution: assess daytime and nighttime cough frequency and any activity limitation. Improvement indicates a positive response to therapy. 4
Rescue medication use: the child should need a SABA on fewer than 2 days per week for good control. 5
Trigger identification: review recent viral infections, exercise, and environmental exposures such as tobacco smoke or allergens. 4
Inhaler technique: verify correct use of the spacer and coordination with the metered‑dose inhaler. 3

Continue the ICS for at least 3 months after cough resolution before considering any step‑down, to ensure stable asthma control. 6
When stepping down, use the lowest effective dose (e.g., budesonide 200–400 µg/day equivalent) that maintains control. 7
Provide a written asthma action plan that outlines when to increase therapy and when to seek urgent care. 3
Educate caregivers that abrupt discontinuation of controller medication can precipitate loss of control and exacerbations. 1

Re‑evaluate the diagnosis after another 2–3 weeks of optimal therapy; lack of improvement warrants consideration of alternative or co‑existing conditions. 7
Post‑viral cough may persist for 3–8 weeks after a respiratory infection and does not require antibiotics. 1
If cough remains refractory, consider referral for bronchoscopy to assess for structural airway abnormalities (identified in roughly one‑third of children with persistent symptoms). 5

Do not assume that the absence of wheeze excludes asthma. 1
Do not prescribe antibiotics for uncomplicated asthma‑related cough; they have no benefit unless bacterial infection is proven. 1
Do not use antihistamines or cough suppressants for asthma‑related cough in children, as they lack proven efficacy. 7
Do not continue ineffective therapy beyond 2–3 weeks without reassessing the diagnosis; escalating the dose without response is unwarranted. 7
Do not restart therapy without addressing adherence barriers (e.g., side‑effect concerns, cost, misunderstanding of the need for a controller). 3

Explain the difference between “reliever” (SABA) and “preventer” (ICS) medications; the preventer must be taken regularly even when the child feels well. 5
Demonstrate proper inhaler technique with a spacer: actuate the MDI, have the child inhale one puff through the spacer, and repeat for each prescribed puff. 2
Instruct parents on red‑flag signs that require urgent care: increased work of breathing, inability to speak in full sentences, or poor response to rescue medication. 4
Emphasize avoidance of environmental triggers, especially tobacco smoke exposure, which is a major modifiable risk factor for persistent cough. 1